Commercializing the Stem Cell Sciences

By

  • Olivia Harvey, University of Sydney, Australia

Promising new developments in biomedical technology such as stem cell science are widely endorsed by governments keen to reduce spiralling healthcare costs, clinicians focused on patient care, and patients demanding revolutionary new treatments. Commercializing the stem cell sciences offers a comparative analysis of the commercial methods adopted in the global stem cell industries. It seeks to establish whether there is an optimum commercial model and to examine what emerging companies can learn from their predecessors. Following an introduction to stem cell sciences and the problems involved in their commercialization, the book begins with a discussion of stem cell treatments from a global perspective, and the role of innovation in the commercialization of biotechnology in general. In the second half of the book, chapters focus on the different strategies that can be employed and their relative risks and values, before a conclusion that looks at potential new developments in the field.
View full description

Audience

Physicians and scientists interested in transplanting scientific discovery into clinical therapies; Scientists involved in regenerative medicine therapies; Researchers in stem cell biology and bioengineering

 

Book information

  • Published: October 2012
  • Imprint: Woodhead Publishing
  • ISBN: 978-1-907568-60-2


Table of Contents

Introduction: Stem cell science, biotechnology and the problem of commercialization; Stem cell treatments in a global marketplace; The role of innovation systems in the commercialization of biotechnology; Low-risk, low-value: Adult stem cells; High-risk, high-value: Embryonic stem cells; Low-risk, low-value: iPS cells; What does the future hold?